Drug · Other
Pegaspargase
CI-DRUG-00000698Explore in graph →CHEMBL2108546 Approved
Regulatory
Approvals (7)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as ONCASPAR (DIN 02461900) under ATC L01XX24 PEGASPARGASE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Jun 1, 2017 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as ONCASPAR (DIN 02236849) under ATC L01XX24 PEGASPARGASE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Jan 2, 2004 | Oct 13, 1998 | health-canada-dpd |
| EU EMA | Acute Lymphoblastic Leukemia | Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients. | approved | Jan 14, 2016 | ema |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 7 hours agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 33 | 14 | 45 | 125 | 7 | CA, EU, US | Feb 1, 1994 | 1994-07 |
| Leukemia | Approved | Phase 4 | 26 | 10 | 37 | 99 | 3 | EU, US | Feb 1, 1994 | 1996-03 |
| Non-Hodgkin Lymphoma | Phase3 | Phase 3 | 11 | 4 | 13 | 39 | 0 | — | — | Sep 12, 2006 |
| Malignant Central Nervous System Neoplasm | Phase3 | Phase 3 | 1 | 1 | 2 | 2 | 0 |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (126)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06554626 | Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL | recruiting | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06527781 | A Study of PD5K3 in Healthy Adult Volunteers | completed | Phase 1 |